Peptides vs Antibodies: How the Two Biologic Classes Differ

Drug classes

Peptides vs antibodies is not a contest between a weak drug and a strong one. It is a contest between a molecule of a few dozen amino acids and one of roughly 150,000 daltons, and almost every practical difference between the two classes follows from that thirty-to-three-hundred-fold gap in size. Both are “biologics” in the loose sense, both are mostly injected, and both are built from the same twenty amino acids. But size decides how long each lasts in the blood, where each can go, what each can bind, how each is manufactured, and how the immune system treats it. This guide walks through those consequences one at a time.

What counts as a peptide and what counts as an antibody?

Therapeutic peptides are usually defined as chains of fewer than about fifty amino acids with molecular weights of roughly 500 to 5,000 daltons. The boundary is fuzzy at the top: insulin, with 51 residues, is routinely filed as a peptide even though it sits just over the line. Peptides can be linear, cyclic, lipidated or otherwise modified, and the majority of modern examples are analogues of a natural hormone that has been edited to survive longer in the body.

A monoclonal antibody is a different order of object. A therapeutic IgG is a Y-shaped protein of about 150 kilodaltons made of two identical heavy chains and two identical light chains held together by disulphide bonds. The tips of the Y carry the variable regions that recognise the target; the stem, the Fc region, is what the immune system and the FcRn recycling receptor recognise. Evolocumab, an anti-PCSK9 antibody, is listed on its FDA label at approximately 144 kDa and is produced in Chinese hamster ovary cells, which is a typical description for the class.

The rest of this comparison is essentially a list of what follows from thirty-fold or more difference in mass.

Peptides vs antibodies: half-life and the kidney filter

The single most consequential difference is how long each survives in circulation. Native peptides are small enough to pass through the kidney’s glomerular filter and are also exposed to proteases in blood and tissue. Native GLP-1, the gut hormone behind an entire class of diabetes and obesity drugs, has a plasma half-life of about two minutes because the enzyme DPP-4 clips it and the kidney removes what is left. Every marketed GLP-1 drug is an engineering answer to that two-minute problem: amino-acid substitutions that block DPP-4, a fatty-acid tail that binds albumin, or fusion to something large.

Antibodies sit far above the filtration cut-off and, more importantly, carry an Fc region. The neonatal Fc receptor, FcRn, binds IgG inside the acidic endosomes of cells that have taken it up and returns it to the bloodstream instead of letting it be digested. That recycling is why endogenous IgG persists for around three weeks and why therapeutic antibodies typically show half-lives of roughly 11 to 30 days. Evolocumab’s label gives an effective half-life of 11 to 17 days.

The two mechanisms can be combined. Dulaglutide is a GLP-1 analogue covalently attached to a modified IgG4 Fc, producing a 63 kDa hybrid with an elimination half-life of about five days. The peptide provides the pharmacology; the Fc borrows the antibody’s clearance behaviour. The half-life extension strategies guide covers the other tricks in that toolbox.

Where each molecule can go

Size also sets the map of reachable targets. Because antibodies are large and polar they stay largely confined to the vasculature and the interstitial space between cells. That is fine for a circulating target like PCSK9 or a receptor sitting on a cell surface, and it is exactly why so many antibody drugs are aimed at those. It is a hard limit for anything inside a cell: a monoclonal antibody cannot cross the cell membrane.

Peptides occupy the middle ground. They are small enough to diffuse into tissue and, with appropriate design, some can cross membranes; a whole research field exists around cell-penetrating peptides. They are also large enough to do something small molecules struggle with: bind flat, featureless protein-protein interfaces. A 2017 review of cyclic peptides in the 700 to 2,000 dalton range argued that they can reach antibody-like affinity on such interfaces, which small molecules cannot manage and antibodies cannot reach from outside the cell. That is the “undruggable target” argument for the class, and it is the reason macrocyclic peptides attract so much design effort.

How each is made

Manufacturing follows from chemistry rather than biology for one class and the reverse for the other. Peptides up to a few dozen residues are typically built by solid-phase peptide synthesis, the resin-based method Merrifield introduced in 1963, and that chemistry is what lets designers drop in unnatural amino acids, D-amino acids and backbone modifications that no cell would produce. The solid-phase synthesis guide explains the cycle.

Antibodies are too large to synthesise chemically. They are expressed in living cells, overwhelmingly Chinese hamster ovary cells grown in bioreactors, then purified in multi-step downstream processes. This is expensive infrastructure, though the cost has fallen sharply: a Gates Foundation white paper on low-cost antibody manufacturing puts typical cost of goods at over 50 dollars per gram of drug substance, down from roughly 1,000 dollars per gram two decades earlier, and notes that cost of goods is usually under a tenth of the sales price. Peptide production is generally described as simpler and cheaper, but a like-for-like per-gram comparison is hard to source and is not given here.

The hybrids again straddle the line. Dulaglutide, being an Fc fusion, is made in CHO cells. Romiplostim, a “peptibody” that joins an IgG1 Fc to thrombopoietin-receptor-binding peptides, is made in E. coli. Caplacizumab, the first approved nanobody, is also produced in E. coli, which a full-size glycosylated IgG cannot be.

Immunogenicity: who gets attacked?

Any injected protein can provoke anti-drug antibodies, and the history of the antibody class is largely a history of reducing that risk. The first approved monoclonal, muromonab-CD3 in 1986, was fully mouse-derived, and mouse antibodies are recognised as foreign, cleared rapidly and can trigger allergic reactions. The naming convention that followed encoded the fix: -omab for mouse, -ximab for chimeric, -zumab for humanised and -umab for fully human, a source infix the naming bodies finally dropped in 2017 as it became less informative. The drug-naming guide covers the parallel convention for peptides.

Even fully human antibodies are not invisible. The adalimumab label reports low-titre anti-drug antibodies in about 5 percent of adult rheumatoid-arthritis patients (58 of 1,062), rising to 12 percent on monotherapy and falling to 1 percent with concomitant methotrexate. Evolocumab’s label reports binding antibodies in 0.3 percent (48 of 17,992) and no neutralising antibodies.

Peptides are often described as low-immunogenicity, and the label data broadly support “lower, not zero”. The teriparatide label states plainly that “as with all peptides, there is potential for immunogenicity” and reports cross-reacting antibodies in 3 percent of women (15 of 541), with no hypersensitivity and no effect on calcium or bone density. Dulaglutide’s label reports anti-drug antibodies in 1.6 percent of patients (64 of 3,907), 0.9 percent neutralising.

Route, dosing interval and the oral exception

Both classes are overwhelmingly injected. Antibodies are given intravenously or subcutaneously, and their long half-life allows dosing every two weeks to every few months. Peptides are mostly subcutaneous, with intervals from daily to weekly depending on how much half-life engineering they carry. The exception that proves the rule is oral semaglutide: the tablet co-formulates the peptide with salcaprozate sodium, an absorption enhancer, and the label instructs that it be taken at least 30 minutes before any food, drink or other oral medicine. The oral peptide delivery guide explains why that workaround was necessary. No full-size antibody is taken by mouth.

Scorecard: peptides vs antibodies at a glance

One target, both approaches: PCSK9

The cleanest way to see the trade-offs is a target that both classes have reached. PCSK9 is a circulating protein that lowers the number of LDL receptors on liver cells; block it and LDL cholesterol falls. Evolocumab, a 144 kDa human IgG2 given by subcutaneous injection every two weeks or monthly, was the antibody answer. In July 2026 the FDA approved enlicitide, described in the agency’s announcement as a macrocyclic peptide and the first oral PCSK9 inhibitor, taken as a once-daily 20 mg tablet. In the CORALreef Lipids phase 3 trial (NCT05952856, 2,912 participants) the sponsor reported a placebo-adjusted LDL-C reduction of 55.8 percent at week 24. Same target, same biology, two entirely different molecules: an injected antibody that lasts weeks, and a swallowed peptide taken daily. Which one a patient ends up on is a clinical decision that belongs with a prescriber; what the pair shows is that the two classes are complements more often than rivals.

Frequently asked questions

Are peptides biologics?

It depends on the regulator’s definition. In US law a chemically synthesised chain of 40 or fewer amino acids is regulated as a drug, not a biologic, while larger proteins and cell-made products fall under biologics licensing. Colloquially both peptides and antibodies get called biologics because both are built from amino acids.

Why are antibodies so much more expensive to make?

They must be produced by living cells and purified from everything else those cells make, whereas short peptides can be assembled on a resin by chemistry. Antibody cost of goods has fallen dramatically, but the plant and process are still heavier.

Can a peptide be as selective as an antibody?

Selectivity is about the binding surface, not the size of the molecule. Well-designed cyclic peptides reach antibody-like affinities on protein-protein interfaces, but achieving that for a new target typically takes far more design work than raising an antibody.

What is a nanobody?

A single-domain antibody fragment derived from the heavy-chain-only antibodies of camelids. Caplacizumab, the first approved example, joins two humanised domains with a short linker to give a 28 kDa molecule, small enough to be made in bacteria and to diffuse into tissue more readily than a full IgG.

Informational only — not medical advice · 21+. Nothing here is dosing or treatment guidance. Decisions about any prescription antibody or peptide medicine belong with a qualified healthcare professional.